Not Too ATTRACTive Data For Catheter Thrombolysis In Combatting Post-Thrombotic Syndrome

Randomized trial results show pharmacomechanical, catheter-directed thrombolysis does not reduce the development of post-thrombotic syndrome in patients treated for deep-vein thrombosis. The study’s investigator suggests limiting the procedure to treatment of large iliofemoral blood clots causing major symptoms in patients who are at low risk of bleeding.

blood clot
• Source: shutterstock.com

Two-year results of the ATTRACT trial show that pharmacomechanical catheter-directed thrombolysis (PCDT) to treat deep-vein thrombosis does not reduce the patients’ chances of developing post-thrombotic syndrome, but does increase their risk of major bleeding compared anticoagulation drug therapy alone.

“[ATTRACT] provides the first high quality data on PCDT and will enable doctors to target its use to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiology

Boston Scientific Raises Outlook … Again: Headwinds Offset By EP And Watchman

 

Agent drug coated balloon, Watchman product sales, and electrophysiology (EP) business unit growth offset Acurate discontinuation and tariff headwinds. CEO Michael Mahoney shouted out coronary therapies business and answered questions on CMS proposed Ambulatory Surgical Center codes.

Injuries And Deaths Linked To Baxter Infusion Pump

 

The US FDA says Baxter has notified customers about an issue with its Novum IQ Syringe Pump that is linked to two deaths and multiple injuries.

HeartFlow Takes Another Crack At Public Markets With $100M IPO Filing

 
• By 

AI heart imaging company HeartFlow filed for a $100m IPO after scrapping its 2022 SPAC plans. It remains unprofitable but is betting on FDA clearances, Medicare coverage and a demand for AI-powered diagnostics to win over investors.

Abbott Lowers Outlook But Headwinds Are Temporary

 

Despite headwinds, executives remain optimistic about growth in Abbott’s medical devices and diabetes divisions and plan several product rollouts, including the Volt PFA catheter for electrophysiology and the dual glucose-ketone sensor CGM.

More from Device Area

Siemens Healthineers Mitigates Headwinds With ‘Value-Add Structural Changes’

 

Siemens Healthineers anticipates €400m-€500m tariff impact by 2026 but says it will mitigate losses through structural changes and pricing. Despite a revenue decline in diagnostics due to China’s VBP, diagnostics transformation activities, including cutting product, were “successful."

Biostate AI Builds Global RNA-AI Pipeline With $12M Boost, Ventures In China And India

 
• By 

Biostate AI has set up an Indian subsidiary, Bayosthiti, to develop cancer and cardiac diagnostics with local hospitals. This follows a joint venture with China's Kindstar Global and mirrors Biostate’s US collaboration with Mass General Brigham to build AI models for melanoma.

CorTec Begins First Human Trial Of Wireless Brain Implant For Stroke Rehab

 
• By 

Germany’s CorTec has implanted its wireless brain-computer interface in a stroke patient, launching a trial to test safety and whether brain stimulation during physical therapy can help restore movement where traditional rehab has failed.